Cybin Reveals Promising Results in Depression Treatment

Cybin (TSE:CYBN) has released an update.

Cybin Inc. has unveiled promising 12-month efficacy results from its CYB003 program at the American College of Neuropsychopharmacology Annual Meeting, demonstrating significant response and remission rates in major depressive disorder patients. Additionally, findings from their DMT studies suggest enhanced therapeutic effects when combined with SSRIs, potentially offering new hope for patients unresponsive to traditional antidepressants.

For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.